Affordable Access

A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.

Authors
Type
Published Article
Journal
ClinicoEconomics and outcomes research : CEOR
Publication Date
Volume
1
Pages
53–59
Identifiers
PMID: 21935307
Source
Medline
Keywords
License
Unknown

Abstract

Within the Italian health care system, intermittent etanercept is a cost-effective therapeutic option compared with nonsystemic therapy for the group of patients with moderate and severe plaque psoriasis. For patients with PASI ≥ 20, cost-effectiveness of etanercept is even greater.

Statistics

Seen <100 times